Summary of study ST001256

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000842. The data can be accessed directly via it's Project DOI: 10.21228/M8V694 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST001256
Study TitleMetabolic landscape remodeling in dystrophic muscle through glucocorticoid steroid regimens
Study SummaryDuchenne muscular dystrophy is caused by genetic defects in the gene encoding dystrophin and leads to progressive muscle degeneration. Glucocorticoid steroids are current mainstay pharmacological regimen to decrease muscle inflammation and prolong the ambulatory period in these patients, but daily intake of glucocorticoids like prednisone and deflazacort causes adverse side effects like osteoporosis, adrenal suppression, insulin resistance and obesity. Intermittent steroid dosing has been proposed as alternative to maintain benefits and limit side effects, but a detailed understanding of the mechanisms underpinning the regimen-specific effects in muscle is still missing. Here we explore how once-daily versus once-weekly prednisone (4 week-long treatment) affect the metabolomic landscape in mdx mouse muscle (genetic model of Duchenne muscular dystrophy; DBA/2J background) through metabolomics profiling.
Institute
Northwestern University
Last NameQuattrocelli
First NameMattia
Address303 East Superior St, SQBRC 5-500, Chicago, IL, 60611, USA
Emailmattia.quattrocelli@northwestern.edu
Phone3125037450
Submit Date2019-09-26
Num Groups3
Total Subjects9
Num Males9
Raw Data AvailableYes
Raw Data File Type(s).raw
Analysis Type DetailLC-MS
Release Date2020-01-06
Release Version1
Mattia Quattrocelli Mattia Quattrocelli
https://dx.doi.org/10.21228/M8V694
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000842
Project DOI:doi: 10.21228/M8V694
Project Title:Metabolic landscape remodeling in dystrophic muscle through glucocorticoid steroid regimens
Project Summary:Duchenne muscular dystrophy is caused by genetic defects in the gene encoding dystrophin and leads to progressive muscle degeneration. Glucocorticoid steroids are current mainstay pharmacological regimen to decrease muscle inflammation and prolong the ambulatory period in these patients, but daily intake of glucocorticoids like prednisone and deflazacort causes adverse side effects like osteoporosis, adrenal suppression, insulin resistance and obesity. Intermittent steroid dosing has been proposed as alternative to maintain benefits and limit side effects, but a detailed understanding of the mechanisms underpinning the regimen-specific effects in muscle is still missing. Here we explore how once-daily versus once-weekly prednisone (4 week-long treatment) affect the metabolomic landscape in mdx mouse muscle (genetic model of Duchenne muscular dystrophy; DBA/2J background) through metabolomics profiling.
Institute:Northwestern University
Department:Center for Genetic Medicine
Laboratory:McNally Laboratory
Last Name:Quattrocelli
First Name:Mattia
Address:303 East Superior St, SQBRC 5-500, Chicago, IL, 60611, USA
Email:mattia.quattrocelli@northwestern.edu
Phone:3125037450
Funding Source:NIH, PPMD, MDA
Contributors:Quattrocelli, McNally

Subject:

Subject ID:SU001324
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090
Genotype Strain:DBA/2J-mdx
Age Or Age Range:6 months
Gender:Male

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA091299McN-Mat-20180411-07daily prednisone
SA091300McN-Mat-20180411-09daily prednisone
SA091301McN-Mat-20180411-08daily prednisone
SA091302McN-Mat-20180411-03vehicle
SA091303McN-Mat-20180411-02vehicle
SA091304McN-Mat-20180411-01vehicle
SA091305McN-Mat-20180411-05weekly prednisone
SA091306McN-Mat-20180411-04weekly prednisone
SA091307McN-Mat-20180411-06weekly prednisone
Showing results 1 to 9 of 9

Collection:

Collection ID:CO001318
Collection Summary:3 vehicle control samples; 3 once-daily prednisone (1mg/kg i.p.) samples; 3 once-weekly prednisone (1mg/kg i.p.) samples. Each sample was extracted from ~100mg quadriceps muscle mass (one per mouse). Total hydrophilic metabolite content was extracted from quadriceps muscle tissue at treatment endpoint through methanol:water (80:20) extraction, adapting conditions described previously (Bruno et al., 2018). Briefly, total metabolite content from quadriceps muscle was obtained from ~100mg (wet weight) quadriceps muscle tissue per animal. Frozen (-80°C) muscle was pulverized in liquid nitrogen and homogenized with ~250l 2.3mm zirconia/silica beads (Cat # 11079125z, BioSpec, Bartlesville, OK) in 1ml methanol/water 80:20 (vol/vol) by means of Mini-BeadBeater-16 (Cat # 607, Biospec, Bartlesville, OK) for 1 minute. After centrifuging at 5000rpm for 5 minutes, 200l of supernatant were transferred into a tube pre-added with 800L of ice-cold methanol/water 80% (vol/vol). Samples were vortexed for 1 min, and then centrifuged at ~20,160 xg for 15 min at 4°C. Metabolite-containing extraction solution was then dried using SpeedVac (medium power).
Sample Type:Muscle

Treatment:

Treatment ID:TR001339
Treatment Summary:3 vehicle control samples; 3 once-daily prednisone (1mg/kg i.p.) samples; 3 once-weekly prednisone (1mg/kg i.p.) samples. Each sample was extracted from ~100mg quadriceps muscle mass (one per mouse). Treatment duration was four weeks. Samples were collected 48 hours after last prednisone injection.

Sample Preparation:

Sampleprep ID:SP001332
Sampleprep Summary:Total hydrophilic metabolite content was extracted from quadriceps muscle tissue at treatment endpoint through methanol:water (80:20) extraction, adapting conditions described previously (Bruno et al., 2018). Briefly, total metabolite content from quadriceps muscle was obtained from ~100mg (wet weight) quadriceps muscle tissue per animal. Frozen (-80°C) muscle was pulverized in liquid nitrogen and homogenized with ~250l 2.3mm zirconia/silica beads (Cat # 11079125z, BioSpec, Bartlesville, OK) in 1ml methanol/water 80:20 (vol/vol) by means of Mini-BeadBeater-16 (Cat # 607, Biospec, Bartlesville, OK) for 1 minute. After centrifuging at 5000rpm for 5 minutes, 200l of supernatant were transferred into a tube pre-added with 800L of ice-cold methanol/water 80% (vol/vol). Samples were vortexed for 1 min, and then centrifuged at ~20,160 xg for 15 min at 4°C. Metabolite-containing extraction solution was then dried using SpeedVac (medium power).

Combined analysis:

Analysis ID AN002085
Analysis type MS
Chromatography type HILIC
Chromatography system Thermo Ultimate3000
Column Waters XBridge Amide (100 x 4.6mm, 3.5um)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo Q-Exactive
Ion Mode UNSPECIFIED
Units peak area values

Chromatography:

Chromatography ID:CH001522
Chromatography Summary:200ul of 50% Acetonitrile were added to the tube for reconstitution following by overtaxing for 1 min. Samples solution were then centrifuged for 15 min @ 20,000g, 4°C. Supernatant was collected for LC-MS analysis for Hydrophilic Metabolites Profiling as follows. Samples were analyzed by High-Performance Liquid Chromatography and High-Resolution Mass Spectrometry and Tandem Mass Spectrometry (HPLC-MS/MS). Specifically, system consisted of a Thermo Q-Exactive in line with an electrospray source and an Ultimate3000 (Thermo) series HPLC consisting of a binary pump, degasser, and auto-sampler outfitted with a Xbridge Amide column (Waters; dimensions of 4.6 mm × 100 mm and a 3.5 µm particle size). The mobile phase A contained 95% (vol/vol) water, 5% (vol/vol) acetonitrile, 20 mM ammonium hydroxide, 20 mM ammonium acetate, pH = 9.0; B was 100% Acetonitrile. The gradient was as following: 0 min, 15% A; 2.5 min, 30% A; 7 min, 43% A; 16 min, 62% A; 16.1-18 min, 75% A; 18-25 min, 15% A with a flow rate of 400 μL/min.
Instrument Name:Thermo Ultimate3000
Column Name:Waters XBridge Amide (100 x 4.6mm, 3.5um)
Chromatography Type:HILIC

MS:

MS ID:MS001936
Analysis ID:AN002085
Instrument Name:Thermo Q-Exactive
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:The capillary of the ESI source was set to 275 °C, with sheath gas at 45 arbitrary units, auxiliary gas at 5 arbitrary units and the spray voltage at 4.0 kV. In positive/negative polarity switching mode, an m/z scan range from 70 to 850 was chosen and MS1 data was collected at a resolution of 70,000. The automatic gain control (AGC) target was set at 1 × 106 and the maximum injection time was 200 ms. The top 5 precursor ions were subsequently fragmented, in a data-dependent manner, using the higher energy collisional dissociation (HCD) cell set to 30% normalized collision energy in MS2 at a resolution power of 17,500. The sample volumes of 25 μl were injected. Data acquisition and analysis were carried out by Xcalibur 4.0 software and Tracefinder 2.1 software, respectively (both from Thermo Fisher Scientific).
Ion Mode:UNSPECIFIED
  logo